BioLineRx Q2 Revenue Down 55% YoY, CEO Optimistic About Pipeline Expansion Opportunities

BioLineRx reported Q2 EPS of 0c, in line with last year, and Q2 revenue of $300K, missing consensus of $661.33K. The company had $28.2M in cash and short-term bank deposits as of June 30, 2025, enough to fund operations into H1 2027. CEO Philip Serlin said discussions with potential partners are progressing, and the company is seeing promising opportunities for pipeline expansion and long-term value creation.

BioLineRx Ltd. (NASDAQ: BLRX) reported its second-quarter 2025 financial results, with GAAP EPS of $0.00, in line with the same period last year. The company's revenue for the quarter stood at $5.39 million, falling short of the consensus estimate of $661.33 million. As of June 30, 2025, BioLineRx had $28.2 million in cash and short-term bank deposits, providing sufficient funding to support operations into the first half of 2027 [1].

CEO Philip Serlin stated that discussions with potential partners are progressing, and the company is seeing promising opportunities for pipeline expansion and long-term value creation. BioLineRx is actively evaluating a broad range of potential pipeline expansion opportunities in the areas of oncology and rare diseases, leveraging its clinical and regulatory expertise and track record of drug approval success [2].

The company's financial results indicate a significant improvement in its cash runway guidance, extending from the second half of 2026 to the first half of 2027. This extension is primarily attributed to a strong balance sheet and the shutdown of U.S. commercial operations following the Ayrmid transaction in November 2024 [2].

In the clinical update, BioLineRx reported continued enrollment activities in the CheMo4METPANC Phase 2b clinical trial, which is evaluating motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapy. The trial is being led by Columbia University and supported by both Regeneron and BioLineRx. Additionally, the company is progressing with its ongoing Phase 1 clinical trial evaluating motixafortide as a monotherapy and in combination with natalizumab for stem cell mobilization for gene therapies in sickle cell disease [2].

APHEXDA generated sales of $1.7 million in the second quarter of 2025, providing royalty revenue of $0.3 million to the company. Research and development expenses for the quarter were $2.3 million, compared to $2.2 million for the same period last year. General and administrative expenses decreased to $0.2 million from $1.6 million in the second quarter of 2024 [2].

Management is scheduled to host a conference call today, August 14th, at 8:30 am EDT, to discuss the company's financial results and provide additional updates. Investors can access the conference call by dialing +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally [2].

References:
[1] https://seekingalpha.com/news/4485238-biolinerx-gaap-eps-of-0_00-revenue-of-5_39m
[2] https://finance.yahoo.com/news/biolinerx-reports-second-quarter-2025-110000493.html